Online Program Home
My Program

Abstract Details

Activity Number: 641
Type: Topic Contributed
Date/Time: Thursday, August 4, 2016 : 8:30 AM to 10:20 AM
Sponsor: Biopharmaceutical Section
Abstract #320547 View Presentation
Title: Subgroup Identification in a Learn-and-Confirm Setting
Author(s): Lei Shen*
Companies: Eli Lilly and Company
Keywords: clinical trials ; multiplicity ; simulation ; tailored therapy ; drug development ; biomarkers

There are major challenges in the rigorous identification of patient subgroups with enhanced treatment effect based on data from clinical trials. A typical late phase drug development program consists of multiple studies, which present complexities-since there is more data and more analysis options-as well as opportunities for subgroup identification. We propose an approach to this problem with three key aspects: (1) the multiple analyses should be considered jointly as a learn-and-confirm paradigm; for example, the choice of analysis method for the first trial should be determined with the subsequent analysis in mind; (2) a number of recently developed subgroup identification methods should be utilized, as they provide increased rigor and statistical power over traditional post hoc subgroup analyses; (3) thoughtful simulations should be performed to optimize the learn-and-confirm approach to subgroup identification for a specific application prior to unblinding, with proper considerations given to prior knowledge and meaningful effect sizes. I will present both general considerations and a case study.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2016 program

Copyright © American Statistical Association